Company intelligence / Profile preview

Liposeuticals

Ownership: Private
Development stage: Other

Overview

Liposeuticals has completed full GLP animal toxicology studies and safety pharmacology studies on its sugar-lipid polymer technology. The company has demonstrated bioequivalence of its formulations versus existing marketed emulsion-based preparations and validated complete solubilization of organic APIs with >90% reduction in lipid content compared to currently marketed products. A drug master file (DMF) has been filed with the FDA under review[3].

Therapeutic areas: OncologyOtherInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

12 assets

propofol (Liposeuticals)

Preclinical

11 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Liposeuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liposeuticals.

Explore the full profile